Lipitor reduces cardiovascular risk in diabetes

The licensed indications for Lipitor (atorvastatin) have been extended allowing the statin to be used for the prevention of cardiovascular disease in patients with diabetes who have at least one additional risk factor.

The statin may be used in such patients irrespective of whether their cholesterol levels are raised and even though coronary heart disease is not clinically evident.

The extension to Lipitor's licence follows the results of a major trial involving almost 3,000 patients with type II diabetes, without a prior history of cardiovascular disease and with LDL cholesterol less than 4.14 mmol/L, who had at least one of the following risk factors: hypertension, smoker, retinopathy, microalbuminuria or macroalbuminuria. After 3.9 years on a dose of 10 mg daily, Lipitor significantly reduced the risk of fatal and non-fatal major cardiovascular events such as stroke and myocardial infarction.

Further information: Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS. Tel: (01304) 616161.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more